Methamphetamines clinical trials at UCSF

2 in progress, 1 open to eligible people

Showing trials for

  • Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV

    open to eligible people ages 18-69

    The goal of this clinical trial is to learn whether it is possible to use intramuscular (IM) ketamine in combination with psychotherapy to treat moderate-to-severe methamphetamine use disorder (MeUD) in publicly insured patients with or at-risk for HIV disease. The main questions it aims to answer are: - Do publicly insured patients find ketamine-assisted psychotherapy feasible and acceptable as a potential treatment for MeUD? - Is IM ketamine safe and tolerable among patients with MeUD? Participants will: - Receive 3 monitored doses of IM ketamine - Have 3 preparation and 4 integration psychotherapy visits - Report their daily amounts of methamphetamine used prior to, during, and up to 3 months following the intervention

    San Francicso, California

  • Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM

    Sorry, in progress, not accepting new patients

    This is a double-blind, placebo-controlled phase 2b trial in which 54 MSM who use meth will be randomly assigned (2:1) to receive 12 weeks of as-needed intermittent oral naltrexone 50 mg enhanced with an EMA-informed EMI platform, or receive as-needed placebo with EMA-informed EMI. The 12-week treatment period is consistent with other pharmacotherapy trials for substance use disorders. The proposed sample size is also consistent with other phase 2b trials for substance use treatment. Upon enrollment, participants will complete daily EMA assessments and weekly visits for behavioral surveys and urine testing for meth metabolites, study drug dispensing and computer-based counseling for substance use. Safety laboratory assessments and vital signs will be completed monthly. Efficacy (Specific Aims 1-3) will be assessed upon trial completion as measured by proportion meth-positive urine samples; PrEP and ART adherence by drug levels and viral load testing; and sexual risk behavior data accounting for PrEP use and viral suppression.

    San Francisco, California

Our lead scientists for Methamphetamines research studies include .

Last updated: